Research

Hormonal

GLP-1 receptor agonists reduce the risk of atrial fibrillation by approximately 42% compared to placebo, which is a significant risk factor for stroke.

Taking GLP-1 drugs may also lower your risk of developing atrial fibrillation, a heart rhythm problem that increases stroke risk. This is another way these drugs protect your brain and heart.

GoodSupportsHIGH confidence
In a meta-analysis including 11 RCT, semaglutide was shown to decrease the occurrence of incident AF by almost 42% compared to placebo [30].
Melissa Mariscal et al. · Current Neurology and Neuroscience Reports · 2025

Why this rating

Based on a meta-analysis of 11 randomized clinical trials.

Source

Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke

Melissa Mariscal et al. · Current Neurology and Neuroscience Reports · 2025

DOI 10.1007/s11910-025-01423-9

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →